Logo

Roche Reports Acceptance of BLA for Fixed-Dose SC Combination of Perjeta and Herceptin to Treat HER2-Positive Breast Cancer

Share this

Roche Reports Acceptance of BLA for Fixed-Dose SC Combination of Perjeta and Herceptin to Treat HER2-Positive Breast Cancer

Shots:

  • The BLA is based on P-III FeDeriCa study assessing FDC of Perjeta + Herceptin (SC) + CT vs Perjeta + Herceptin (IV) + CT in 500 patients with HER2-positive eBC who are being treated in the neoadjuvant & adjuvant settings
  • The P-III FeDeriCa study resulted in meeting its 1EPs & 2EPs i.e. non-inferior levels of Perjeta & Herceptin in the blood during a given dosing interval (Ctrough) respectively- demonstrated comparable total pCR- no new signals were identified including no differences in cardiac toxicity
  • The FDC combination is a new SC formulation that combines Perjeta and Herceptin with Halozyme’s Enhanze drug delivery technology which is based on (rHuPH20) with its expected FDA’s approval by Oct 18- 2020

Click here ­to­ read full press release/ article 

Ref: Roche | Image: Roche 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions